---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-043564"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T19:15:34.674055+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IN8bio unveils gamma-delta T cell engager platform with lead candidate INB-619

## Summary
- INB-600 platform expands both Vd1+ and Vd2+ T cells; lead INB-619 targets CD19 for B-cell cancers and autoimmune diseases.
- Preclinical data: up to 450-fold T cell expansion, rapid and sustained B-cell depletion with target cells eradicated.
- Natural lower IL-6 secretion may reduce risk of CRS and neurotoxicity vs. CAR-T and traditional TCEs.
- CEO cites unmet need for deep B-cell depletion with improved safety; plans to seek partners for IND-enabling trials.
- No CRS or neurotoxicities observed to date in IN8bio's ongoing gamma-delta T cell clinical programs.

## SEC filing metadata
- accession: 0001193125-25-043564
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312525043564/0001193125-25-043564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312525043564/d936231d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-043564
- JSON: https://secwatch.observer/filing/0001193125-25-043564.json
- Plain text: https://secwatch.observer/filing/0001193125-25-043564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.